NP Life Sciences Health Industry Group annual cash and equivalents
2019
2020
2021
2022
2023
NP Life Sciences Health Industry Group Cash & Equivalents Growth & History (ACAT)
NP Life Sciences Health Industry Group's cash and equivalents was $70,614 for fiscal 2023.
View full NP Life Sciences Health Industry Group company overviewNP Life Sciences Health Industry Group annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $70,614 | −$51,245 | −42.05% |
| 2022 | 2022-12-31 | $121,859 | $93,873 | +335.43% |
| 2021 | 2021-12-31 | $27,986 | −$90,625 | −76.41% |
| 2020 | 2020-12-31 | $118,611 | −$124,322 | −51.18% |
| 2019 | 2019-12-31 | $242,933 | — | — |
NP Life Sciences Health Industry Group quarterly cash and equivalents
As of Dec 31, 2018
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $6,009 | — | — |
| Q1 2025 | 2025-03-31 | $10,048 | — | — |
| Q4 2023 | 2023-12-31 | $70,614 | −$51,245 | −42.05% |
| Q3 2023 | 2023-09-30 | $84,551 | $77,600 | +1116.39% |
| Q2 2023 | 2023-06-30 | $125,111 | $124,536 | +21658.43% |
| Q1 2023 | 2023-03-31 | $140,078 | $116,956 | +505.82% |
| Q4 2022 | 2022-12-31 | $121,859 | $93,873 | +335.43% |
| Q3 2022 | 2022-09-30 | $6,951 | −$18,059 | −72.21% |
| Q2 2022 | 2022-06-30 | $575 | −$40,153 | −98.59% |
| Q1 2022 | 2022-03-31 | $23,122 | −$66,305 | −74.14% |
| Q4 2021 | 2021-12-31 | $27,986 | −$90,625 | −76.41% |
| Q3 2021 | 2021-09-30 | $25,010 | −$119,984 | −82.75% |
| Q2 2021 | 2021-06-30 | $40,728 | −$127,792 | −75.83% |
| Q1 2021 | 2021-03-31 | $89,427 | −$132,798 | −59.76% |
| Q4 2020 | 2020-12-31 | $118,611 | −$124,322 | −51.18% |
| Q3 2020 | 2020-09-30 | $144,994 | −$131,628 | −47.58% |
| Q2 2020 | 2020-06-30 | $168,520 | — | — |
| Q1 2020 | 2020-03-31 | $222,225 | — | — |
| Q4 2019 | 2019-12-31 | $242,933 | $242,733 | +121366.50% |
| Q3 2019 | 2019-09-30 | $276,622 | — | — |
| As of Dec 31, 2018 | 2018-12-31 | $200 | — | — |
NP Life Sciences Health Industry Group cash and equivalents trends
Between the periods ended 2019-12-31 and 2023-12-31, NP Life Sciences Health Industry Group's cash and equivalents decreased from $242,933 to $70,614, a change of −$172,319. The latest reported quarter, Q2 2025, shows $6,009.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NP Life Sciences Health Industry Group source filings ↗